financial guidance

The company said its sales team will serve healthcare providers by telephone and online until it's safe to return to the field.

The skin cancer diagnostics company said it delivered 37 percent more DecisionDx-Melanoma test results in Q4 2019 than in the previous year's fourth quarter.

More than 70 percent of ePlex analyzer placements in the fourth quarter were within labs that previously had a competitive analyzer, the firm said.

The company said testing revenues rose 54 percent during the quarter, and that it provided 63 percent more patient results year over year.

Test volumes, revenues per test and costs per test improved during the quarter, the company said.

Adaptive said that Q4 clinical testing volume for its ClonoSeq sequencing assay for minimal residual disease increased 66 percent to 3,218 tests.

Opko recorded $177.9 million in service revenues, $32 million in product revenues, and $14.4 million from licensing and the transfer of intellectual property revenues.

Billable test volume for the company's ConfirmMDx prostate cancer test fell 5 percent year over year, but global volume for its SelectMDx test rose 61 percent.

For the three months ended Jan. 31, the firm's revenues rose to $1.36 billion from $1.28 billion, beating analysts' average estimate of $1.35 billion.

Diagnostics revenues for the fourth quarter were $1.76 billion, up 4 percent from $1.69 billion in the same quarter last year.